State Street Corp Genprex, Inc. Transaction History

State Street Corp

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.76 - $1.78 $32,452 - $76,006	42,700 Added 32.91%	172,439 $156,000
Q2 2022 Aug 15, 2022	SELL	$1.28 - $2.31 $588 - $1,062	-460 Reduced 0.35%	129,739 $180,000
Q1 2022 May 16, 2022	BUY	$1.82 - $3.5 $37,450 - $72,019	20,577 Added 18.77%	130,199 $294,000
Q3 2021 Nov 15, 2021	BUY	$2.59 - $3.36 $22,274 - $28,896	8,600 Added 8.51%	109,622 $294,000
Q2 2021 Aug 16, 2021	SELL	$3.11 - $4.87 $1.41 Million - $2.21 Million	-454,350 Reduced 81.81%	101,022 $338,000
Q1 2021 May 17, 2021	BUY	$3.66 - $7.67 $347,392 - $728,005	94,916 Added 20.61%	555,372 $2.39 Million
Q4 2020 Feb 16, 2021	BUY	$3.03 - $5.51 $94,923 - $172,617	31,328 Added 7.3%	460,456 $1.91 Million
Q3 2020 Nov 10, 2020	SELL	$2.9 - $4.29 $13,891 - $20,549	-4,790 Reduced 1.1%	429,128 $1.44 Million
Q2 2020 Aug 14, 2020	BUY	$1.99 - $3.64 $863,496 - $1.58 Million	433,918 New	433,918 $1.36 Million

600

Ticker GNPX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 48,020,300
Market Cap $64.3M
Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

Stay updated on State Street Corp with notifications on news.